SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company with a current market capitalization of ...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at ...
Hosted on MSN14d
HeartBeam submits 510(k) application to FDA for ECG softwareHeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram (ECG) synthesis software tailored to assess various cardiac rhythms and ...
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/106.BfLtBoPo.js ...
The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical ...
The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12 ...
Overview: HeartBeam, Inc. is a medical technology company that develops and commercializes ambulatory electrocardiogram solutions for cardiac disease detection and monitoring in various settings, with ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback